Healthcare · Profile from Healthcare Research Companion
Walgreens Boots Alliance, Inc.
The Chicago-area drugstore chain that for most of the twentieth century was America's largest pharmacy, merged with Britain's Boots and Stefano Pessina's Alliance UniChem wholesale empire to form the world's first global pharmacy-led health and wellbeing company (2014), and then spent a decade discovering that size alone did not protect a pharmacy without a PBM or an insurer. Its moves include an ambitious international merger, a failed attempt to buy Rite Aid, the Theranos blood-testing partnership, a multibillion-dollar bet on VillageMD primary care that was largely written off, opioid settlements, mass store closures and, in August 2025, a ~$10bn take-private by Sycamore Partners that split the company into five private businesses.
At a glance
- Founded
- 1901, Chicago, when pharmacist Charles R. Walgreen Sr. bought the drugstore where he worked; incorporated as Walgreen Co. in 1916
- Founders
- Charles Rudolph Walgreen Sr. (Walgreen Co.); Boots founded by John Boot in Nottingham (1849); Alliance UniChem built by Stefano Pessina and Ornella Barra from an Italian wholesaler (1977 onward)
- Headquarters
- Deerfield, Illinois (Walgreens); Nottingham, UK (Boots)
- Ownership / structure
- Private since August 28, 2025, owned by Sycamore Partners (with Pessina reinvesting, reported). Previously Nasdaq: WBA (2014–2025) and Walgreen Co. (NYSE, then Nasdaq; public from 1927, per company histories). After the buyout the former WBA operates as five standalone private companies: Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD (reported)
- Leadership (2026)
- Mike Motz, CEO of Walgreens (from August 2025; ex-Staples US Retail, Shoppers Drug Mart); John Lederer, executive chairman (reported). Earlier CEOs: Greg Wasson (2009–2015), Stefano Pessina (2015–2021), Rosalind Brewer (2021–2023), Tim Wentworth (2023–2025)
- Segment
- Pharmacy (retail, specialty, mail); front-store retail; wholesale (international, largely sold 2021); US Healthcare (VillageMD, Shields, CareCentrix)
- Payer and patient
- Prescription revenue paid by PBMs and plans (commercial, Medicare Part D, Medicaid) plus patient cost-sharing; front-store sales paid by consumers; NHS England payments for Boots pharmacies
- Scale
- ~8,500 US stores and ~12,500 globally at peak (reported; falling after closures); ~$147.7bn revenue in fiscal 2024 (reported); ~300,000+ employees before cuts (verify)
- Capital / price
- Alliance Boots stake and combination (~$6.7bn for 45% in 2012; remaining 55% for ~$15bn+ in 2014, reported); VillageMD investments ~$6.2bn (2020–21); Sycamore take-private at $11.45/share plus up to $3.00 contingent per share, ~$10bn equity, up to ~$23.7bn including debt and contingent payments (2025)
- Signature moves (incl. failures)
- Founding and soda-fountain drugstore model (1901–); Alliance Boots combination (2012–14); AmerisourceBergen distribution pact (2013); Theranos wellness centres (2013–16); Rite Aid merger blocked and store purchase (2015–18); VillageMD majority and "Walgreens Health" (2020–23); opioid settlements (2022); VillageMD write-downs and store closures (2024); Sycamore take-private (2025)
9 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1901
Founding Charles Walgreen
Founding
2012
Alliance Boots Combination
Acquisition in two steps / merger
2013
AmerisourceBergen Distribution Pact
Partnership / strategic investment
2013
Theranos Wellness Centers
Partnership / launch (failure)
2015
Rite Aid Deal Blocked
Acquisition (abandoned under antitrust pressure) / asset purchase
2021
VillageMD Majority and Walgreens Health
Acquisition (majority stake) / strategic pivot
2022
Opioid Settlement
Regulatory / litigation settlement
2024
VillageMD Writedown and Store Closures
Restructuring / write-down / store closures
2025
Sycamore Take Private
Acquisition (private-equity take-private / LBO)